microRNA expression profiling of early primary breast cancer to identify prognostic markers and associated pathways
Retrospective series of primary breast cancer patients who received surgery between 1989 and 1992. Patients received adjuvant chemotherapy and/or adjuvant hormone therapy, or no adjuvant treatment. Tamoxifen was used as endocrine therapy for 5 years in ER+ BC patients. Patients who were <50 years of age, with lymph node positive tumors, or ER– and/or >3 cm in diameter, received adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for six cycles, in a thrice weekly intravenous regime...
Provenance — who produced it, who reused it
Linked to 17 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- MicroRNA-30c inhibits human breast tumour chemotherapy resistanc... 2013 · 238 cites
- Prognostic microRNA/mRNA signature from the integrated analysis... 2013 · 153 cites
- miR-506 Regulates Epithelial Mesenchymal Transition in Breast Ca... 2013 · 100 cites
- MicroRNA-30c targets cytoskeleton genes involved in breast cance... 2012 · 99 cites
- Circulating miR-200c and miR-141 and outcomes in patients with b... 2015 · 94 cites
- Integration of mRNA Expression Profile, Copy Number Alterations,... 2014 · 76 cites
11 further papers cite this accession but reuse could not be confirmed.
Deep data QC
metadata only · no data-level QC for this typeStandardized, field-standard QC computed by touching the data — every metric states how it was obtained
No quantitative QC rubric exists for this data type yet, so it is deliberately left unscored — this is an honest "not applicable", not a poor rating.
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0 · provisional — verify independently